Literature DB >> 7772645

The psychotropic effects of inhibitors of steroid biosynthesis in depressed patients refractory to treatment.

A M Ghadirian1, F Engelsmann, V Dhar, D Filipini, R Keller, G Chouinard, B E Murphy.   

Abstract

Twenty patients, diagnosed as suffering from treatment-resistant major depression, were treated with one or more drugs that decrease corticosteroid biosynthesis. Nine were psychotic, 11 nonpsychotic. Seventeen completed the treatment (8 psychotic, 9 nonpsychotic); 13 responded (5 psychotic, 8 nonpsychotic; 11 responded completely (i.e., a drop in the Hamilton Depression Scale of at least 50%, to < or = 15), and 2 responded partially. The mean age of the responders (45.2 +/- 12.6 years) did not differ significantly from that of the nonresponders (48.7 +/- 12/3). Data were analyzed in the following categories; (1) the presence or absence of psychosis, (2) response or nonresponse to treatment, and (3) the drug(s) used (aminoglutethimide, ketoconazole, or a combination of either of these with metyrapone). The patients improved over time on the Hamilton Depression Scale independent of the medication used. Responders demonstrated improvement in mood, insomnia, anxiety, diurnal variation, paranoia and obsessive compulsiveness. Nonpsychotics responded better than psychotics.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7772645     DOI: 10.1016/0006-3223(94)00150-2

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  10 in total

Review 1.  [New developments in pharmacotherapy of depression].

Authors:  R Rupprecht; Th C Baghai; H-J Möller
Journal:  Nervenarzt       Date:  2003-05-10       Impact factor: 1.214

Review 2.  Psychotic major depression: a benefit-risk assessment of treatment options.

Authors:  Audrey R Tyrka; Lawrence H Price; Marcelo F Mello; Andrea F Mello; Linda L Carpenter
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

Review 3.  Glucocorticoid inhibition in the treatment of depression: can we think outside the endocrine hypothalamus?

Authors:  Mitchel A Kling; Victoria H Coleman; Jay Schulkin
Journal:  Depress Anxiety       Date:  2009       Impact factor: 6.505

4.  Diagnostic and therapeutic advances in treatment-resistant mood disorders.

Authors:  B J Blinder; A R Bloom
Journal:  West J Med       Date:  1996-03

Review 5.  Hormone treatment of depression.

Authors:  Russell T Joffe
Journal:  Dialogues Clin Neurosci       Date:  2011       Impact factor: 5.986

6.  Antiglucocorticoids as Treatments for Depression : Rationale for Use and Therapeutic Potential.

Authors:  L H Price; R T Malison; C J McDougle; G H Pelton
Journal:  CNS Drugs       Date:  1996-05       Impact factor: 5.749

Review 7.  Therapeutic options for treatment-resistant depression.

Authors:  Richard C Shelton; Olawale Osuntokun; Alexandra N Heinloth; Sara A Corya
Journal:  CNS Drugs       Date:  2010-02       Impact factor: 5.749

8.  Attenuation of hypothalamic-pituitary-adrenocortical hyperactivity in depressed patients by mirtazapine.

Authors:  Cornelius Schüle; Thomas Baghai; Peter Zwanzger; Robin Ella; Daniela Eser; Frank Padberg; Hans-Jürgen Möller; Rainer Rupprecht
Journal:  Psychopharmacology (Berl)       Date:  2003-01-28       Impact factor: 4.530

9.  Crossroads of corticotropin releasing hormone, corticosteroids and monoamines. About a biological interface between stress and depression.

Authors:  H. M. Van Praag
Journal:  Neurotox Res       Date:  2002 Aug-Sep       Impact factor: 3.911

10.  Study protocol for the randomised controlled trial: antiglucocorticoid augmentation of anti-Depressants in Depression (The ADD Study).

Authors:  R Hamish McAllister-Williams; Eleanor Smith; Ian M Anderson; Jane Barnes; Peter Gallagher; Heinz C R Grunze; Peter M Haddad; Allan O House; Tom Hughes; Adrian J Lloyd; Elaine M M McColl; Simon H S Pearce; Najma Siddiqi; Baxi Sinha; Chris Speed; I Nick Steen; June Wainright; Stuart Watson; Fiona H Winter; I Nicol Ferrier
Journal:  BMC Psychiatry       Date:  2013-08-03       Impact factor: 3.630

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.